Skip to content

A Safety and Effectiveness Study of Brahmi Ghrita in Healthy Individuals, Comparing Traditional and Nano-Formulations, Followed by a Detox Therapy

A Phase 1 Clinical Study and Pharmacokinetic Analysis of Snehapana Using Brahmi Ghrita in Healthy Volunteers Along with a Biosimilar Comparative Analysis of Nano-encapsulated Brahmi Ghrita Followed by Virechana - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/090425
Enrollment
30
Registered
2025-07-08
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Sreejith Sreekumar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Ambulatory, male or female, 18-45 years of age 2. Overall healthy, having no difficulty with digestion or absorption of food 3. Sneha Yogya 4. Willing and able to give written informed consent 5. Having no clinically significant abnormalities on the basis of medical history, physical examination and vital signs. 6. All values for hematology and clinical chemistry tests of blood within the normal range for age and gender or showing no clinically relevant deviations

Exclusion criteria

Exclusion criteria: 1. Having any medical condition(s) including diabetes, cardiovascular disease, pulmonary, renal, endocrine, hepatic, neurologic, psychiatric, immunologic, hematologic, gastrointestinal or metabolic disease requiring medical treatment that would preclude participation 2. Having had a history of any medical or surgical procedure that would preclude participation 3. Being pregnant, planning on becoming pregnant, breast feeding or unwilling to use a medically acceptable form of birth control during the study

Design outcomes

Primary

MeasureTime frame
Cmax (Peak Plasma Concentration): Identify the highest observed concentration of the active ingredient(s) in plasma.Timepoint: 0.5 hr, 1 hr, 2 hr, 4 hr, 8 hr, 12 hr,24 Hrs, Day 2,Day 3 up to day 7 or till Samyak Snigdha

Secondary

MeasureTime frame
Tmax (Time to Peak Plasma Concentration): Determine the time at which Cmax occurs.Timepoint: 0.5 hr, 1 hr, 2 hr, 4 hr, 8 hr, 12 hr,24 Hrs, Day 2,Day 3 up to day 7 or till Samyak Snigdha;AUC(0-t) (Area Under the Curve from 0 to the Last Measurable Time Point): Calculate the area under the concentration-time curve using trapezoidal or other appropriate methods.Timepoint: 0.5 hr, 1 hr, 2 hr, 4 hr, 8 hr, 12 hr,24 Hrs, Day 2,Day 3 up to day 7 or till Samyak Snigdha;t( ) (Half-life)Timepoint: 0.5 hr, 1 hr, 2 hr, 4 hr, 8 hr, 12 hr,24 Hrs, Day 2,Day 3 up to day 7 or till Samyak Snigdha;Complete Blood CountTimepoint: Pre Study,Day 1,Day 3-7,Day 30;Liver Function TestsTimepoint: Pre Study,Day 1,Day 3-7,Day 30;Lipid ProfileTimepoint: Pre Study,Day 1,Day 3-7,Day 30;Renal Function TestsTimepoint: Pre Study,Day 1,Day 3-7,Day 30;Heena,Ati and Mithya YogasTimepoint: 3 to 7 days;Adverse enentsTimepoint: Base line to End of Study

Countries

India

Contacts

Public ContactSreejith Sreekumar

Glocal College of Ayurvedic Medical Sciences and Research Centre

sreejithorma@gmail.com9995342978

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026